Clinical Efficacy of Bevacizumab Combined with Temozolomide in Treating Gliomas.

BEV plus TMZ is remarkable in the treatment of patients with recurrent malignant gliomas. The combination treatment improves the DCR and PFS of patients and their quality of life, and does not increase adverse reactions, making it a promising approach that deserves widespread promotion and clinical application.